Partner
Cora Holt is an experienced patent litigator at both the trial and appellate levels. A former clerk at the U.S. Court of Appeals for the Federal Circuit, Cora represents clients in patent disputes in district courts across the country, the International Trade Commission (ITC), the Federal Circuit, the U.S. Supreme Court, and the U.S. Patent and Trademark Office (USPTO).
Cora handles cases involving a variety of technologies, with an emphasis on the biotechnology, pharmaceutical, and life sciences industries, including Hatch-Waxman and biologics cases. She has represented clients in cases involving small and large molecules, medical devices, human therapeutic antibodies, gene therapies, drug delivery systems, soybean plants, and engineered microorganisms, to name a few. Her experience spans all aspects of patent litigation, including pre-suit diligence, case strategy, fact and expert discovery, dispositive motions and briefs, pretrial and trial submissions, preparing and examining witnesses at trial, and presenting argument before trial and appellate courts.
In addition to her litigation work, Cora assists clients in portfolio counseling matters and proceedings before the USPTO. She has been recognized as a “Rising Star”, an “IP Star”, and a notable practitioner on the national level by Managing Intellectual Property (MIP) and named to the Best Lawyers 2021 Ones to Watch list. Cora also devotes significant time to pro bono work, particularly the representation of veterans in cases before the Federal Circuit, the U.S. Court of Appeals for Veterans Claims, and the U.S. Court of Federal Claims.
Cora serves as the hiring partner for Finnegan’s Washington, D.C. office.
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
Successfully defended Novartis against Genzyme’s multiple patent infringement actions and inter partes review (IPR) proceedings related to recombinant adeno-associated virus vector technology used in Novartis’ blockbuster, breakthrough gene therapy Zolgensma®. The case settled after four patents were invalidated during claim construction, five patents found not literally infringed, and institution of multiple IPRs.
1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews
Abbott Biotechnology Ltd. v. Centocor Ortho Biotech Inc.
4:09-cv-40089, D. Mass., Judge Saylor
Abbvie Inc. v. The Mathilda and Terence Kennedy Institute of Rheumatology Trust
1:11-cv-02541; 1:13-cv-01358, S.D.N.Y., Judge Crotty
13-1545; 14-1672, Fed. Cir., Judges Chen, Dyk, Wallach, Taranto
Representing Allergan and Pierre Fabre in ANDA litigation in the District of New Jersey against multiple generic drug manufacturers seeking to make a generic version of Fetzima® (levomilnacipran) for the treatment of major depressive disorder.
2:17-cv-10230, D.N.J., Judges Mannion, Salas
Ajinomoto Co., Inc. et al. v. CJ Cheiljedang Corp. et al.
Represented Ajinomoto in the Southern District of New York in litigation involving patents related to genetically modified organisms and the use thereof to make commercial quantities of tryptophan. This representation follows successful representation of Ajinomoto in related IPR proceedings, ITC investigation, and subsequent Federal Circuit appeal.
1:16-cv-03498, S.D.N.Y., Judges Gorenstein, Vyskocil
337-TA-1005, ITC, Judges Bullock, Essex
18-1590, -1629, Fed. Cir., Judges Dyk, Moore, Taranto
IPR2017-01551, -01698, PTAB, Judges Franklin, Mitchell, Moore, Sawert, Yang
American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al.
Counsel for American Regent in litigation in the District of New Jersey against Pharmacosmos and their branded drug, Monoferric®, related to American Regent patents covering the use of iron carbohydrate complexes for the treatment of iron deficiency diseases. The case resulted in a favorable settlement for our client.
PGR2020-00009, PTAB, Judges Tornquist, Franklin, Wisz
3:20-cv-01350, D.N.J., Judges Goodman, Martinotti, Quraishi
Charitable
2024 AIPLA Women in IP DC Community Service Event 2024 AIPLA Women in IP DC Community Service Event
January 23, 2024
Washington
Webinar
Patent Infringement, Safe Harbor, and Drug Development: Navigating the Uncertain Boundaries, Recent Court Treatment Patent Infringement, Safe Harbor, and Drug Development: Navigating the Uncertain Boundaries, Recent Court Treatment
November 30 2023
Webinar
Podcasts
October 2023 - Last Month at the Federal Circuit Podcast Series October 2023 - Last Month at the Federal Circuit Podcast Series
November 2, 2023
Federal Circuit IP Blog
Podcast Series: Last Month at the Federal Circuit - October 2023 Podcast Series: Last Month at the Federal Circuit - October 2023
November 2, 2023
Award/Ranking
61 Finnegan Attorneys Recognized on the 2025 Capital Pro Bono Honor Roll 61 Finnegan Attorneys Recognized on the 2025 Capital Pro Bono Honor Roll
May 7, 2026
Commentary
She Has a Point: Finnegan's Cora Holt She Has a Point: Finnegan's Cora Holt
March 13, 2026
Law360Announcement
Finnegan Announces 2025 Mentors of the Year Finnegan Announces 2025 Mentors of the Year
December 19, 2025
Press Release
Pro Bono: Finnegan Obtains Dismissal of Homicide and Related Charges Against DC Man Pro Bono: Finnegan Obtains Dismissal of Homicide and Related Charges Against DC Man
June 13, 2025
Award/Ranking
Finnegan Remains a Top Tier Firm in the 2025 Managing Intellectual Property IP Stars Rankings Finnegan Remains a Top Tier Firm in the 2025 Managing Intellectual Property IP Stars Rankings
May 30, 2025
Managing Intellectual PropertyAward/Ranking
Finnegan Ranks at the Top of the Managing Intellectual Property IP Stars Rankings Finnegan Ranks at the Top of the Managing Intellectual Property IP Stars Rankings
June 28, 2024
Managing Intellectual PropertyDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.